Tesamorelin vs Sermorelin

Overview

Tesamorelin and sermorelin are both synthetic analogs of growth hormone-releasing hormone (GHRH). Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy, while sermorelin was previously approved but is now only available through compounding pharmacies for off-label use.

Key Facts

Aspect	Tesamorelin	Sermorelin
Class	GHRH analog	GHRH analog
Structure	Modified GHRH 1-44	GHRH 1-29
Brand Name	Egrifta	Geref (discontinued)
FDA Status	Approved	Previously approved
Current Availability	Prescription	Compounding pharmacies

Mechanism Comparison

Aspect	Tesamorelin	Sermorelin
Target	GHRH receptor	GHRH receptor
Amino Acids	44 (with trans-3-hexenoic acid)	29
Action	Stimulates GH release	Stimulates GH release
Half-life	~26 minutes	~10-20 minutes

Structural Differences

Tesamorelin:

• Full-length GHRH (1-44) with modification
• Trans-3-hexenoic acid addition at N-terminus
• Enhanced stability vs native GHRH

Sermorelin:

• Truncated GHRH (first 29 amino acids)
• Retains full biological activity
• Shorter sequence, potentially more immunogenic

Evidence Comparison

Aspect	Tesamorelin	Sermorelin
Human RCTs	Multiple (TESAMORELIN studies)	Historical trials
FDA Review	Full regulatory review	Previous approval
Long-term Data	Yes (years)	Limited recent data
Independent Replication	Yes	Historical

Tesamorelin Clinical Data

Trial	Population	Key Finding
Phase 3	HIV lipodystrophy	Reduced visceral fat ~18%
Extension	HIV lipodystrophy	Sustained effect at 52 weeks

Sermorelin Historical Data

• Originally approved for pediatric GH deficiency (1997)
• Manufacturing discontinued 2008
• Historical trials showed GH stimulation efficacy
• Less recent controlled data available

Efficacy on GH Release

Parameter	Tesamorelin	Sermorelin
GH Increase	Significant	Significant
IGF-1 Increase	~15-25%	Variable
Pulsatile Release	Yes	Yes
Physiological Pattern	Maintained	Maintained

Regulatory Status

Aspect	Tesamorelin	Sermorelin
FDA Status	Approved (2010)	Previously approved
Indication	HIV lipodystrophy	Pediatric GH deficiency
Prescription Required	Yes	Yes (compounded)
Insurance Coverage	For indication	Typically not covered
WADA Status	Prohibited	Prohibited

Administration

Aspect	Tesamorelin	Sermorelin
Route	Subcutaneous	Subcutaneous

Side Effect Profile

Tesamorelin

Effect	Frequency	Notes
Injection site reactions	Common	Erythema, pruritus
Peripheral edema	Common	Fluid retention
Arthralgia	Common	Joint pain
Hyperglycemia	Caution	Monitor glucose

Sermorelin

Effect	Frequency	Notes
Injection site reactions	Common	Redness, swelling
Flushing	Occasional	Facial warmth
Headache	Occasional	Usually mild
Antibody formation	Possible	May reduce efficacy

Comparative Safety

Factor	Tesamorelin	Sermorelin
Safety Database	Large (FDA approved)	Historical
Cancer Monitoring	Required	Recommended
Diabetes Risk	Monitor glucose	Less data
Antibody Development	Possible	Possible

Cost Considerations

Factor	Tesamorelin	Sermorelin
Pricing	High (~$1,000+/month)	Lower (compounded)
Insurance	May cover for HIV	Rarely covered
Quality Assurance	FDA-regulated	Compounding variation

Clinical Applications

Use	Tesamorelin	Sermorelin
HIV Lipodystrophy	FDA approved	Off-label
Anti-aging	Off-label	Off-label
Body Composition	Evidence in HIV	Limited data
Pediatric GHD	Not indicated	Historical use

Key Differences

Factor	Tesamorelin	Sermorelin
Regulatory status	FDA approved	Compounded only
Structure	44 amino acids + modification	29 amino acids
Half-life	Longer	Shorter
Evidence quality	High (modern trials)	Historical
Quality control	FDA regulated	Variable
Cost	Higher	Lower

Summary

• Tesamorelin is FDA-approved with robust clinical data for HIV lipodystrophy
• Sermorelin was previously approved but now only available compounded
• Both stimulate physiological GH release via GHRH receptor
• Tesamorelin has longer half-life and modern safety data
• Sermorelin may be more accessible/affordable through compounding
• Quality and purity concerns exist with compounded peptides

---

This comparison is for educational purposes only. Tesamorelin requires prescription for approved indication. Compounded sermorelin has variable quality. Consult a healthcare provider for treatment decisions.